Fig. 1 · Structure
Documents & Downloads
BMD4503-2
LRP5/6-sclerostin Interaction Inhibitor
BMD4503-2 is a quinoxaline derivative that functions as an inhibitor of LRP5/6-sclerostin interactions. By competitively binding to the LRP5/6-sclerostin complex, BMD4503-2 effectively restores the activity of the Wnt/β-catenin signaling pathway. This compound is valuable for investigating Wnt signaling in various contexts, including bone development, maintenance, and osteoporosis research.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 301357-87-9 |
| Applications | LRP5/6-sclerostin Interaction Inhibitor |
| Formula | C26H21N5O3S |
| Molecular Weight | 483.54 |
| SMILES | CC(NC1=CC=C(C=C1)S(=O)(NC2=NC3=CC=CC=C3N=C2NC4=C5C=CC=CC5=CC=C4)=O)=O |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.